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The efficacy of retrograde coronary venous delivery of 
procainamide for the management of spontaneous and 
inducible sustained ventricular tachycardia was evalu•
ated and compared with systemic intravenous procain•
amide administration in 22 conscious dogs with per•
manent left anterior descending coronary artery occlusion. 
Selective retrograde injection of procainamide was 
achieved through an autoinflatable balloon catheter placed 
in the great cardiac vein, with the tip positioned in the 
vicinity of the site of left anterior descending coronary 
occlusion. Great cardiac vein retroinfusion of procain•
amide was significantly (p < 0.05) more effective than 
systemic intravenous injection against spontaneous ven•
tricular tachycardia 1 day after coronary artery occlu· 
sion (13 dogs) and against electrically induced sustained 
ventricular tachycardia in the 3 to 12 day postocclusion 
period (9 dogs). Significantly lower doses of procain. 
amide were used with retroinfusion as compared with 
systemic administration, that is, 19.6 ± 8.8 versus 
35 ± 0 mg/kg body weight during spontaneous tachy· 
Drug therapy of recurrent sustained ventricular tachycardia 
in the setting of ischemic heart disease is often unsatisfactory 
because these arrhythmias manifest refractoriness to either 
individual or combined antiarrhythmic drug therapy in both 
clinical and experimental settings (1-7). Patients manifest•
ing resistance to antiarrhythmic drug therapy may have de•
ficient or inadequate myocardial distribution of the drug, 
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cardia and 13.4 ± 4.1 versus 32.1 ± 2 mg/kg during 
induced tachycardia (p < 0.01). Retroinfusion of saline 
solution through the great cardiac vein had no effect on 
either type of tachycardia. Myocardial tissue procain•
amide levels measured in infarcted and ischemic zones 
of the left anterior ventricular wall were 9 to 100 times 
higher after great cardiac vein retroinfusion than after 
systemic injection. Great cardiac vein dye injection stud· 
ies demonstrated a preferential distribution in left ven· 
tricular regions supplied by the occluded coronary ar· 
tery. 
It is concluded that regional coronary venous pro•
cainamide retroinfusion in dogs with myocardial infarc· 
tion is more effective than systemic intravenous injection 
against both spontaneous and inducible sustained ven· 
tricular tachycardia. The greater efficacy of great car· 
diac vein treatment appears to be primarily related to 
selectively increased delivery of procainamide to isch· 
emic myocardial sites. 
(J Am Coll CardioI1986;7:551-63) 
especially in and around severely ischemic zones, which 
could be responsible for the initiation and maintenance of 
the tachycardia. Experimental studies in open chest dogs 
(8,9) have shown that myocardial procainamide concentra•
tions were significantly lower in severely ischemic zones 
when the blood flow was reduced to less than 10% of control 
levels. Although the significance of decreased myocardial 
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procainamide concentrations in the severely ischemic zones 
was not studied specifically, it is possible that greatly di•
minished procainamide delivery to critical myocardial sites 
may be a cause of the observed reduction of antiarrhythmic 
effectiveness (6,7). Conversely, enhanced myocardial drug 
delivery to and distribution within ischemic zones could be 
an effective approach to manage otherwise drug-resistant 
ventricular tachycardias. 
In the present study, a conscious canine model of anterior 
myocardial infarction with spontaneous or inducible ven•
tricular tachycardia (10) was used to determine whether 
regional retrograde coronary venous infusion of procain•
amide would increase drug concentration in ischemic myo•
cardial zones and provide effective antiarrhythmic therapy 
(11,12). The great cardiac vein was selected because it 
predominantly drains the zone of left anterior descending 
coronary artery perfusion (13). The effectiveness of coro•
nary venous procainamide retroinfusion is compared with 
that of conventional intravenous procainamide therapy. 
Methods 
Surgical procedures. Sixteen closed chest mongrel dogs 
of either sex weighing from 22 to 26 kg were premedicated 
with morphine sulfate (1 mg/kg body weight, intramuscu•
larly), and anesthetized with sodium pentobarbital (30 to 35 
mg/kg, intravenously). The left anterior descending coro•
nary artery was occluded in the closed chest just proximal 
to its first diagonal branch by inflating the balloon of a 
Fogarty arterial embolectomy catheter (Edwards Labora-
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tories, Incorporated) inserted through the left carotid artery. 
Complete occlusion was confirmed by fluoroscopy by noting 
absence of flow distal to the inflated balloon after the in•
jection of a small amount of contrast medium (Renografin-
76) proximal to the balloon (14), A 7F autoinflatable balloon 
catheter (15) was inserted through the left internal jugular 
vein into the coronary sinus and advanced to the great car•
diac vein where it bifurcates into the anterior intraventricular 
coronary veins, During retrovenous drug injection through 
the tip of this catheter, the balloon automatically inflates, 
thus preventing direct backward shunting from the regional 
coronary veins into the right atrium. The drug is delivered 
retrogradely through the great coronary vein to the specific 
myocardial region supplied by the left anterior descending 
coronary artery. 
Tygon (Teflon) catheters (3,17 mm outer diameter, 1.58 
mm inner diameter) were inserted through the right carotid 
artery to record ascending aortic blood pressure and through 
the right internal jugular vein for systemic intravenous drug 
injection. Two bipolar electrode catheters (USCI) with an 
interelectrode distance of I cm were inserted under fluo•
roscopic control through the left internal jugular vein, one 
into the right atrium and the other to the right ventricular 
outflow tract, to record bipolar electrograms (50 to 500 Hz) 
or to stimulate the right ventricle. The catheters were ex•
teriorized at the neck region of the dog and sutured in place. 
All of these surgical procedures were conducted under sterile 
conditions. The dogs were then returned to their cages for 
recovery. Subsequently, all dogs were studied in a con•
scious, mildly sedated (morphine, 1 mg/kg, intramuscu-
Figure 1. Dog 20. Effect of right ventricular 
overdrive pacing in a conscious dog I day after 
permanent left anterior descending coronary 
artery occlusion. In each panel the upper three 
recordings are electrocardiographic leads I, aVF 
and V \. AoP is aortic blood pressure with 100 
mm Hg calibration and RAEg is the right atrial 
bipolar electrogram, Top panel (control) shows 
the presence of multiform ventricular tachy•
cardia. Right ventricular (RV) overdrive pac•
ing at 200 ms is initiated (arrow, lower left 
panel). Twenty seconds later, overdrive is ter•
minated (arrow, lower right panel); this is 
accompanied by abrupt emergence of the 
tachycardia. 
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larly) state, either 24 hours after left anterior descending 
coronary artery occlusion (13 dogs) or from day 3 to day 
12 after occlusion (9 dogs). Surface electrograms, arterial 
blood pressure and intracardiac recordings were amplified 
using an Electronics for Medicine DR 16 system and re•
corded on magnetic tape (Bell and Howell data tape CPR 
40 I 0) for subsequent selective retrieval (paper speed 50 to 
100 mmls). 
Experimental protocol. Spontaneous ventricular tachy•
cardia. After fluoroscopic confirmation of catheter posi•
tions and completeness of coronary artery occlusion, the 
response of the spontaneous ventricular tachycardia to right 
ventricular overdrive pacing was studied by overdriving the 
ventricle at cycle lengths of 200 to 300 ms for 5 to 20 
seconds (7). Thereafter, the efficacy of procainamide admin•
istration by a given mode was tested in each dog by ad•
ministering incremental bolus doses of procainamide, from 
3 to 5 mg/kg diluted in 5 ml of saline solution. The order 
of intravenous or great cardiac vein mode of procainamide 
injection was randomized. After procainamide testing by a 
particular mode and before the alternate procainamide study, 
baseline spontaneous ventricular tachycardia was estab•
lished in each dog during an intermediate (untreated) period 
of 5 to 6 hours. The latter period is equivalent to approx•
imately 3.5 half-lives for procainamide elimination, assur•
ing adequate time for drug clearance. We also established 
that a residual systemic plasma procainamide level of up to 
3 Itg/ml had no significant effect on the tachycardia. To 
determine the effects of coronary venous administration of 
a nonactive control substance on the tachycardia, saline 
solution was retroinfused during baseline ventricular tachy•
cardia and before each of the two modes of procainamide 
injection. 
For the coronary venous retroinfusion, procainamide di•
luted in 5 ml of normal saline solution and warmed to 37°C 
was administered over a 5 second period and immediately 
followed by a 5 second retrograde 5 ml saline flush at 37°C. 
Thus, for each retroinfusion the coronary vein remained 
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occluded for a total of 10 seconds. Incremental doses of 
procainamide were then administered at 2 minute intervals 
until the tachycardia was suppressed or until a 35 mg/kg 
dose of procainamide was attained. The entire cumulative 
dose of procainamide was given within 10 minutes and the 
overall duration of coronary vein occlusions did not exceed 
45 seconds. 
Inducible sustained ventricular tachycardia. Of the orig•
inal 15 dogs in this series, 2 died on the first day after 
occlusion. Four additional dogs were not included in the 
study either because the occlusion balloon catheter was dis•
placed (two dogs) or because tachycardia could not be in•
duced (two dogs). Electrophysiologic studies were under•
taken in the remaining nine dogs. An attempt was made to 
induce sustained ventricular tachycardia, that is, tachycardia 
requiring electrical intervention for termination either by 
overdrive ventricular pacing (65 of 70 episodes) or by trans•
thoracic shock (5 of 70 episodes). Induction of ventricular 
tachycardia by programmed electrical stimulation was 
achieved by first applying a single premature stimulus (S2) 
scanning the entire cardiac cycle (twice diastolic current 
threshold, 2 ms in duration) during regular ventricular drive 
at cycle lengths of 500 to 300 ms. If tachycardia was not 
induced, S2 was first fixed 10 to 15 ms outside the refractory 
period, and then a second premature stimulus, S3 (with 
characteristics similar to those of S2), was applied until 
refractoriness was encountered or sustained tachycardia was 
induced (whichever occurred first). The sequence was re•
peated with a third premature stimulus, S4, with S3 set 10 
to 15 ms outside the refractory period as in S2, until tachy•
cardia was induced or refractoriness encountered. Induction 
of tachycardia was then repeated to ensure reproducibility 
in all nine dogs. 
To evaluate the efficacy of intravenous and coronary 
venous procainamide for the prevention of sustained ven•
tricular tachycardia induction, the tachycardia was first ter•
minated by overdrive right ventricular pacing. Incremental 
bolus doses of procainamide (2.5 to 35 mg/kg) were then 
Table 1. Comparative Efficacy of Great Cardiac Vein (OCV) and Systemic Intravenous (IV) 
Procainamide Administration on Ventricular Tachycardia and Blood Pressure Response: Relation 
to Systemic Plasma Procainamide Level 
Heart Rate 
Procainarnide 
(beats/min) Blood Pressure Cumulative Dose Plasma Level 
and Rhythm (mm Hg) (mglkg) (lLg/ml) 
Control (0 '" 13) 200 ± 40 (VT) 127 ± 22;82 ± 13 
Procaioarnide 
GCV (0'" II) 121 ± 13t (NSR) 138 ± 19;93 ± 12* 20 ± 9 34 ± 14 
IV (0 = 10) 166 ± 16* (VT) 119 ± 16;84 ± II 35 ± ot 57 ± 23t 
Saline solution 
GCV (n = 0); 202 ± 41 (VT) 124 ± 21;82 ± 4 
*p < 0.05 compared with control; tp < 0.01 compared with intravenous administration. tSaline was 
retroinfused io all 13 dogs; n = number of dogs io which procainarnide was effective, except in control. NSR 
= normal sinus rhythm; VT '" ventricular tachycardia. Values are expressed as mean ± SO. 
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injected either intravenously or into the great cardiac vein, 
with repeat electrical stimulation after each test dose of 
procainamide. 
Measurement of procainamide concentration. Plasma 
procainamide levels were measured before and 5 minutes 
after each mode of injection, and these levels were related 
to the tachycardia response. In addition, myocardial pro•
cainamide concentrations were also obtained from infarcted 
and border and normal zones of the heart, after either in•
travenous or coronary venous injections. For this purpose 
the dogs were reanesthetized not less than 20 hours after 
the previous procainamide study injection. After a control 
plasma sample was obtained, procainamide was injected 
either intravenously (three dogs with spontaneous and three 
dogs with inducible tachycardia) or into the great cardiac 
Figure 2. Dog 11. Inefficacy of systemic intravenous procain•
amide administration to suppress spontaneously occurring ven•
tricular tachycardia in a conscious dog 1 day after permanent left 
anterior descending coronary artery occlusion. Top panel shows 
ventricular tachycardia at a rate of 192 beats/min during control 
conditions. After intravenous (IV) administration of 20 mg/kg of 
procainamide, causing a peak plasma level of 28.3 ~g/ml of pro•
cainamide, tachycardia was not suppressed (lower left panel). 
After an additional injection of 15 mg/kg of procainamide (total 
35 mg/kg), causing a peak plasma level of 51 ~g/ml of procain•
amide (lower right panel), tachycardia was still not suppressed; 
however, its rate was decreased to 162 beats/min. Abbreviations 
and organization of figure as in Figure 1. 
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vein (three dogs with spontaneous and five dogs with in•
ducible tachycardia). Five minutes after the injection the 
dogs were killed and their heart rapidly excised and cut into 
six transverse sections from apex to base. Regional myo•
cardial samples were then taken for measurement of pro•
cainamide concentration. Both plasma and myocardial pro•
cainarnide levels were measured by the homogeneous enzyme 
immunoassay technique (16). 
Histopathologic examinations. Just before the dogs were 
killed, 5 ml of monastral blue and 5 ml of monastral red 
dye (Dupont) were injected to delineate grossly the areas 
of myocardial procainamide distribution. When red dye was 
injected into the great cardiac vein, blue dye was simulta•
neously injected into the left ventricle in an attempt to delin•
eate the areas of both retrograde and anterograde myocardial 
perfusion. Areas of myocardial necrosis were evaluated by 
planimetry after gross staining of the myocardium by the 
triphenyltetrazolium chloride technique (17). For histologic 
evaluation, sections 6 f.L thick were stained with hematox•
ylin-eosin or with toluidine blue. 
Statistical analysis. Comparisons of data obtained by 
the various interventions to either prevent tachycardia in•
ducibility or terminate an established tachycardia were made 
by the analysis of variance using the chi-square exact Fisher 
test. Normal sinus rhythm was considered to be present 
when 100% of the ventricular depolarizations were of sinus 
origin for at least 3 minutes. Data are presented as mean 
± SD. 
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Results 
Spontaneous Ventricular Tachycardia 
Tachycardia configuration and effect of overdrive 
pacing (Fig. 1). All 13 dogs had spontaneous sustained late 
phase ventricular tachycardia (16 to 26 hours after occlu•
sion) with a heart rate ranging from 140 to 310 beats/min 
(mean 199 ± 39.9). Ventricular tachycardia was defined 
as three consecutive beats of ventricular origin at a rate 
greater than 100 beats/min. Although 2 of the dogs with 
tachycardia of 140 and 155 beats/min exhibited short in•
tervening periods of normal sinus rhythm lasting 2 to 8 
seconds, the remaining 11 dogs had no such episodes of 
sinus rhythm, and tachycardia in all of the dogs in the present 
series was considered sustained. The QRS complexes of the 
tachycardias had a multiform configuration in all dogs. Mean 
systolic and diastolic aortic blood pressure during the tachy•
cardias was 126.8 ± 22 and 81.6 ± 13.3 mm Hg, re•
spectively (Table 1). 
In each dog, overdrive right ventricular pacing at two or 
more cycle lengths between 200 and 300 ms was applied 
for periods of 5, 10 and 20 seconds. This, however, could 
not terminate the tachycardia and had no effect on the tachy•
cardia rate or configuration. 
Effects of systemic intravenous procainamide (Fig. 
2). In 10 of the 13 dogs studied, incremental doses of sys•
temic intravenous procainamide up to 35 mg/kg were in•
effective in suppressing the tachycardias (Table 2). In three 
dogs, intravenous procainamide at a mean dose of 30 ± 3 
mg/kg promptly suppressed the tachycardia and restored 
normal sinus rhythm at a mean rate of 132.5 ± 17 beats/min 
for 3 to 7 minutes (mean 4.2 ± 2.1); thereafter, ventricular 
ectopic activity reemerged gradually and developed within 
3 hours to a tachycardia with the originally observed rate 
and QRS configuration. In the 10 dogs in which normal 
sinus rhythm could not be restored despite a total cumulative 
dose of 35 mg/kg, there was a significant (p < 0.05) de•
crease in the rate of the tachycardia without a significant 
change in aortic blood pressure (Table 1). 
Effects of great cardiac vein procainamide retroin•
fusion (Fig. 3). This mode of procainamide delivery was 
effective in suppressing the tachycardia in 11 of the 13 dogs 
studied and promptly restored normal sinus rhythm (Table 
2). This retroinfusion effect was statistically significant when 
compared with the systemic intravenous route of procain•
amide treatment (p < 0.01). The mean rate of reestablished 
normal sinus rhythm was 121.5 ± 13.1 beats/min (range 
95 to 135) and lasted 11.3 ± 3.2 minutes (range 3 to 18), 
which was comparable with the duration after systemic pro•
cainamide administration (p > 0.1). Thereafter, ventricular 
ectopic beats reemerged progressively, and after 3 to 4 hours 
tachycardia reemerged, similar in rate and QRS configu•
ration to that noted before procainamide retroinfusion. In 
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the two dogs in which a cumulative retrograde dose of 35 
mg/kg of procainamide was ineffective, the rate of tachy•
cardia decreased from 215 to 182 and from 197 to 166 
beats/min, respectively. Systolic blood pressure did not change 
after a mean dose of 19.6 ± 8.8 mg/kg procainamide re•
troinfusion; however, a small but significant (p < 0.05) 
increase in diastolic blood pressure was noted (Table 1). 
Effect of normal saline infusion on ventricular tachy•
cardia (Fig. 4). Coronary venous retroinfusion of normal 
saline solution had no effect on either spontaneously oc•
curring ventricular tachycardia or aortic blood pressure on 
all 13 dogs tested (Tables 1 and 2). 
Plasma and myocardial procainamide concentra•
tions. As expected, the mean peak plasma procainamide 
concentration after systemic intravenous injection of 35 mglkg 
was significantly higher (p < 0.01) than that after a mean 
cumulative dose of 19.6 ± 8.8 mg/kg of procainamide by 
retroinfusion (Table 1). In contrast, myocardial procain•
amide concentrations in the ischemic and infarcted left ven•
tricular wall were up to 100 times higher (range 70 to 300 
p,g/g) after great cardiac vein retroinfusion than after sys•
temic intravenous administration (range 0 to 3 p,g/g). 
Inducible Sustained Ventricular Tachycardia 
Coronary venous retroperfusion. Figure 5 illustrates 
the efficacy of great cardiac venous retroinfusion of pro•
cainamide in a representative experiment in which sustained 
ventricular tachycardia was induced (cycle length 235 ms) 
4 days after permanent left anterior descending coronary 
artery occlusion. Retroinfusion of 5 mg/kg of procainamide 
prevented reinduction of the arrhythmia, even after the ap•
plication of triple premature stimuli. Three hours after the 
coronary venous procainamide retroinfusion, when a "pre•
drug" control ventricular tachycardia could again be in•
duced by a single premature stimulus, a cumulative intra•
venous procainamide infusion of 15 mg/kg was administered 
over 2 minutes. This failed to prevent induction of tachy•
cardia (Fig. 6). 
Table 2. Comparative Efficacy of Great Cardiac Vein (GCV) 
and Systemic Intravenous (IV) Procainamide Administration on 
Spontaneous Ventricular Tachycardia in Conscious Dogs, 24 
Hours After Permanent Left Anterior Descending Coronary 
Artery Occlusion 
Conversion to NSR No Conversion to NSR 
(no. of dogs) (no. of dogs) 
Procainamide 
GCV II 2 
IV 3* 10 
Saline solution 
GCV at 13 
*p < 0.01; tp < 0.001 compared with procainamide administration 
by great cardiac vein (chi·square test). Abbreviations as in Table I. 
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Figure 3. Dog 11 (same dog as in Fig. 2). Efficacy of great cardiac 
vein retroinfusion of procainamide in suppressing spontaneously 
occurring ventricular tachycardia in a conscious dog I day after 
permanent left anterior descending coronary artery occlusion and 
6 hours after intravenous procainamide injection. Top panel (con•
trol) shows ventricular tachycardia at a rate of 285 beats/min before 
great cardiac vein (GCV) injection of 10 mg/kg of procainamide 
(6 hours after intravenous injection of procainamide). After the 
injection (lower left panel), a peak plasma level of 8.8 J,tg/ml of 
procainamide was achieved and the rate of the tachycardia was 
slowed. An additional 10 mg/kg of procainamide promptly ter•
minated the tachycardia and normal sinus rhythm resumed. The 
peak plasma level of procainamide during normal sinus rhythm 
was 21.5 J,tg/ml. Abbreviations and organization of figure as in 
Figure 1. 
Table 3 summarizes the results obtained in the nine dogs 
and indicates a significantly (p < 0.05) greater efficacy of 
coronary venous compared with intravenous procainamide 
administration. The mean effective dose of coronary venous 
procainarnide was significantly (p < 0.01) lower than the 
mean intravenous dose of procainamide (13.5 ± 4.1 versus 
32.1 ± 2 mg/kg). In two dogs, intravenous procainamide 
(35 and 25 mg/kg, respectively) proved effective in pre•
venting tachycardia induction. In the same two dogs coro•
nary venous procainamide injection effectively prevented 
tachycardia inducibility at a much lower dose (5 and 10 
mg/kg, respectively). In the six dogs in which intravenous 
procainarnide was ineffective in preventing tachycardia in•
duction. a significant dose-dependent decrease in the rate 
of the induced tachycardia was noted (from 295 ± 19 to 
219 ± 24 beats/min). Similarly, in the two dogs that did 
, ,.'.' 
not respond to coronary venous procainamide (even at a 
maximal cumulative dose of 35 mg/kg), the rate of tachy•
cardia decreased from 315 to 205 and from 336 to 216 
beats/min, respectively. Saline (vehicle) retroinfusion was 
tested in all nine dogs (18 episodes, Table 3) and had no 
significant effect on either tachycardia inducibility or the 
rate of the tachycardia. 
The mean duration of the effect of coronary venous pro•
cainamide on prevention of tachycardia inducibility was 
16.1 + 5.9 minutes (range 5 to 35). During this period, 
tachycardia could not be induced even with a greater number 
of premature stimuli than needed during the predrug control 
period. Short runs of tachycardia (5 to 10 seconds) could 
be induced during 1 hour after the coronary venous injection. 
Table 3. Comparative Efficacy of Intravenous (IV) Versus 
Great Cardiac Vein (GCV) Procainamide Administration in the 
Prevention of Inducible Sustained Ventricular Tachycardia 
Tachycardia 
Drug 
No. of 
Inductiont 
Dose 
Episodes Yes No (mglkg) 
Procainamide 
IV (n = 8) 20 18 (6) 2 (2) 32 ± 2 
GCV (n = 9) 18 6 (3) 12 (6) 13 ± 4* 
Saline solution 
GCV (n = 9) 18 18 (9) 0(9) 
*p < 0.01. tNumbers in parentheses indicate number of dogs. GCV 
versus IV procainamide, p < 0.05; GCV procainamide versus saline so•
lution, p < 0.01; IV procainamide versus saline solution, NS. Abbrevi•
ations as in Table I. 
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Sustained ventricular tachycardia at a rate similar to that 
during the control period could be reinduced 3 to 4 hours 
after coronary venous injection, In one dog, after control 
electrical induction and coronary venous procainamide ter•
mination of a sustained ventricular tachycardia (rate 374 
beats/min), retroinfusion of 10 mg/kg of procainamide spon•
taneously induced ventricular tachycardia at a rate of 430 
beats/min, which degenerated to ventricular fibrillation within 
14 seconds, Repeat attempts with transthoracic shocks to 
cardiovert the fibrillation failed. Unfortunately, the effect 
of intravenous procainamide in this setting could not be 
tested in this dog. In another dog, after control studies of 
tachycardia induction and termination within 4 minutes of 
a cumulative intravenous dose of 25 mg/kg of procainamide, 
ventricular tachycardia of similar configuration but slower 
rate (220 versus 285 beats/min) was induced without elec•
trical stimulation. This tachycardia was easily terminated 
with overdrive ventricular pacing. 
Efficacy of coronary venous versus systemic intra•
venous procainamide (Table 4). Figure 7 illustrates the 
efficacy of great cardiac vein procainamide administration 
in a dog with induced sustained ventricular tachycardia (cycle 
length 270 ms) 6 days after permanent left anterior descend•
ing coronary artery occlusion. Retroinfusion of 10 mg/kg 
of procainamide promptly terminated the tachycardia and 
led to resumption of normal sinus rhythm. The rate of the 
last 10 beats of the tachycardia was progressively decreased 
by 9% before termination. In contrast, intravenous pro•
cainamide (Fig. 8) did not terminate the established tachy•
cardia. Table 4 summarizes the comparative results obtained 
Figure 4. Comparative effects of great cardiac vein retroinfusion 
of normal saline solution and procainamide in a conscious dog 
with spontaneously occurring ventricular tachycardia 1 day after 
permanent occlusion of the left anterior descending coronary ar•
tery, This figure is organized in the same fashion as in Figure I, 
with the addition of the right ventricular bipolar electrogram (R VEg) 
at the bottom of each panel. The top panel shows a control run 
of ventricular tachycardia. Retroinfusion of 10 ml of normal saline 
solution through the great cardiac vein (GCV) (lower left panel) 
had no detectable effect on the tachycardia. In contrast, retroin•
fusion of 10 mg/kg of procainamide through the great cardiac vein 
(lower right panel) promptly terminated the tachycardia and nor•
mal SinUS rhythm resumed. This was associated with a peak plasma 
level of 8.3 J-Lg/ml. Abbreviations as in Figure I. 
Table 4. Comparative Efficacy of Intravenous (IV) Versus 
Great Cardiac Vein (GCV) Procainamide Administration in the 
Termination of Induced Sustained Ventricular Tachycardia 
Procainamlde 
IV 
GCV 
Saline solution 
GCV 
No, of 
Episodes 
8 
12 
12 
Tachycardia 
Termination Reinductlon 
3 (1 of 5 3 (1 dog) 
dogs) 
12 (5 of5 4 (2 dogs) 
dogs) 
0(5 dogs) 
Drug 
Dose 
(mg/kg) 
31 ± 2 
14 ± 2* 
*p < 0.01. Great cardiac vein versus intravenous procainamide; p < 
0,01; great cardiac vein procainarnide versus saline solution. p < 0.01; 
intravenous procainamide versus saline solution, NS. 
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in five dogs with established sustained ventricular tachy•
cardia. In all five dogs, coronary venous procainamide 
promptly terminated the established tachycardia, whereas 
intravenous procainamide was effective in only one of the 
five dogs studied. Intravenous procainamide, however, sig•
nificantly decreased the rate of the tachycardia from a mean 
of 305 ± 12 to 207 ± 18 beats/min (p < 0.01). 
The mean effective dose of coronary venous procain•
amide (14 ± 1.7 mg/kg) was significantly (p < 0.01) less 
than the intravenous dose (31 ± 2.5 mg/kg). After termi•
nation of the established tachycardia by either route, tachy-
., .+J, 
-'. \ r-'· \r' \. '\,' \t \ ~ry.-,Vo-IV 
... fl· 
......... '\ .. /..1'-1 V~"/",i·l .. -;.l .... --' .. /·,-I .. /\ 
., .+,H. 
":"v-" \r.lv \. \' V ... ..."..."\ro ",,--
. .' ., /.;.,' , ... : ",-' tv'!, 
,"-.JI-. 11'-1" ~ J" "~,, \ -
_. '~!'-"/'/~.""-',".-.',/"o"""'/~" 
• ~ : I .' • 
I-.~-; (..;, /', /. (. f'-t-·r .. J,..-
, • J •• ' • 
" . 
---~I--";-'-'-'- ----':.-,--,-,-,--
r .. 
\ " rOo, 1\. • ", '"",. ] 1 00 
.-- ,....., 1""00 .......... ·h... ....., mmHg 
50 
1 sec 
Figure 5. Induction of sustained ventricular tachycardia with a 
single premature stimulation (arrow) during regular ventricular 
drive in a dog 5 days after left anterior descending coronary oc•
clusion (control, top panel). After the interruption of tachycardia 
by ventricular overdrive (not shown), 5 mg/kg of procainamide 
injected into the great cardiac vein (GCV) (bottom panels) pre•
vented reinduction of ventricular tachycardia by single, double and 
triple extrastimuli (arrows). VEg = right ventricular electrogram; 
other abbreviations as in Figure I. 
CONTROL 
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Figure 6. Induction of sustained ventricular 
tachycardia with a single premature stimulus 
(arrow) during regular ventricular drive in a dog 
5 days after permanent left anterior descending 
artery occlusion (top panel, control) and 3 hours 
after great cardiac vein injection of procain•
amide. After interruption of the tachycardia by 
ventricular overdrive (not shown), 5 mg/kg of 
procainamide was administered intravenously 
(LV.); tachycardia, however, was still inducible 
although at a slower rate (bottom left panel). 
Despite an additional 10 mg/kg of procainamide 
(total 15 mg/kg), tachycardia was again induced 
with a single premature stimulus (arrow) (bot. 
tom right panel). Abbreviations as in Figures 
I and 5. 
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CONTROL 5 sec after 10 mg/kg PA by GCV 
50mmHgI ____ V_T_R_~_r_E_2_9_5_b_,_m_in __ __ VT TERMINATION 
cardia was still inducible, although at a slower rate, in one 
dog after intravenous procainamide and in two dogs after 
coronary venous procainamide administration. Saline injec•
tion in all dogs had no effect on the established tachycardia. 
Blood pressure response (Table 5). A significant de•
crease in both systolic and diastolic blood pressures was 
seen after intravenous procainamide administration. In con•
trast, coronary venous retroinfusion caused a significant de•
crease only in systolic blood pressure, while diastolic and 
mean arterial pressures remained unchanged. Diastolic, sys•
tolic and mean arterial blood pressures were significantly 
(p < 0.01) higher after coronary venous procainamide re•
troinfusion than after systemic intravenous injections. 
Plasma and myocardial procainamide concentration 
(Table 5). Plasma procainamide levels were measured 5 
1 sec 
Figure 7. Termination of established monomorphic sustained ven•
tricular tachycardia (YT) by the administration of 10 mg/kg of 
procainamide (PA) into the great cardiac vein (GCY) in a dog 6 
days after permanent left anterior descending coronary artery oc•
clusion (left panel). In the right panel the last 4 seconds of the 
tachycardia is shown, just before tachycardia termination and re•
sumption of normal sinus rhythm. Abbreviations as in Figure 1. 
minutes after drug administration during successful preven•
tion of tachycardia inducibility and during termination of 
established sustained ventricular tachycardia. After coro•
nary venous retroinfusion, these plasma levels were signif•
icantly lower than the levels after intravenous injection (20 
± 11.6 versus 65.3 ± 13.3 JLg/ml, respectively) (p < 
0.001). N-acetyl procainamide (NAPA) plasma levels were 
less than 0.3 JLg/ml in all dogs during the entire study period. 
CONTROL 
AVF 
AoP 
50;Hg I _______ VT __ R_A_T_E_330 _ b_/nl_· __ _ 
3 min after 20 mg/kg IV PA 3 min after 35 mg/kg IV PA 
Figure 8. Inability of intravenous procainam•
ide (35 mg/kg) to terminate established induced 
sustained ventricular tachycardia in a dog 6 days 
after permanent left anterior descending coro•
nary artery occlusion. Top panel (control) shows 
monomorphic sustained ventricular tachycardia 
(YT) 3 minutes after administration of 20 mg/kg 
intravenous (IY) procainarnide (PA) (bottom left 
panel); the rate ofthe tachycardia was decreased 
from 330 to 255 beats/min. An additional 20 
mg/kg (total 35 mg/kg) of procainamide further 
decreased the tachycardia rate (210 beats/min) 
without termination. Abbreviations as in Fig•
ure I. 
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Table 5. Relation Between Plasma Procainamide Levels and Blood Pressure Response After 
Intravenous (IV) and Great Cardiac Vein (GCV) Administration of Procainamide in Eight Dogs 
Procamamide 
Blood Pressure 
Plasma Level Mean Dose 
Systolic Diastolic Mean (lLg/ml) (mg/kg) 
Control 135 :i: 14 87 :i: 9 103 :i: 10 
Procainamide 
GCV 119 :i: 3* 85 :i: 4 96 :i: 3 20 :i: 12 14 :i: 2 
IV 107 :i: 5t 79 :i: 3t 88 :i: 3* 65 ± 13t 31 :i: 2 
*p < 0.01; tp < 0,001; tp < 0.05 (m comparison with control values). All values are mean ± SD. All 
blood pressure values after great cardiac vein procainamide retroinfuslOn were slgmficantly (p < 0.0 I) higher 
than after intravenous injections. 
Myocardial to serum procainamide ratios after intrave•
nous injections ranged from 1.3 to 3.2:1 in noninfarcted 
and from 1.01 to 1.2:1 in infarcted zones (n = 3). In 
contrast, myocardial to serum procainamide ratios after 
coronary venous procainamide retroinfusion ranged from 9 
to 11:1 in infarcted zones and from 3.2 to 3.6:1 in nonin•
farcted zones (n = 5). 
Myocardial dye distribution after great cardiac vein 
and systemic intravenous administration. Figure 9 illus•
trates normal, infarcted and border regions of myocardium 
after simultaneous left ventricular injection of monastral 
blue dye and coronary venous injection of monastral red 
dye. Most of the dye retroinfused through the coronary vein 
distributed over the anterior wall of the left ventricle into 
regions supplied by the occluded artery. Various degrees of 
staining were consistently seen in all preparations within 
the general zone of the infarct, including the subepicardial 
ariel subendocardial regions overlying the infarcted zone (n 
= 6). The least amount of dye after coronary venous re•
troinfusion was seen in the posterior septum and the pos•
terior papillary muscle. The demarcation between the an•
terior and the posterior wall distribution was variable; in 
some cases it was sharply delineated and in others it was 
less distinct. In contrast, areas of dye distribution after left 
ventricular injection were mostly confined to the posterior 
wall of the left ventricle, with no or very little staining in 
the anterior wall, including the infarct zone. Myocardial 
zones bordering the infarct appeared to be within the ter•
ritory of both left ventricular and coronary venous routes 
of drug delivery (zone of overlap) because both dyes were 
present in these zones. Mean myocardial infarct size esti•
mated by planimetry was 23.5 ± 15.2% (range 18.5 to 
35.6) of the left ventricle. 
Discussion 
The major finding of this study in a conscious canine 
model of myocardial infarction is that great cardiac vein 
procainamide retroinfusion is significantly more effective 
than systemic intravenous administration in controlling and 
suppressing both spontaneous and inducible sustained ven-
tricular tachycardia. Procainamide was selected as a model 
antiarrhythmic drug in these studies for a number of reasons. 
First, procainamide is safe and has been shown to manifest 
demonstrable antiarrhythmic efficacy in ischemic heart dis•
ease (3,18,19). Second, its short half-life (2 hours in our 
experimental studies) makes it convenient for repeat drug 
testing. The return to the predrug state of ventricular tachy•
cardia 4 to 5 hours after drug administration indicates that 
adequate washout bf procainamide did in fact occur before 
repeat testing with the alternate procedure. 
Antiarrhythmic mechanisms in coronary venous pro•
cainamide retroinfusion. The greater efficacy of coronary 
venous procainamide was unrelated to the systemic plasma 
level of the drug. As expected, significantly lower systemic 
plasma procainamide levels were seen in dogs with coronary 
venous retroinfusion. Similar systemic plasma procainamide 
levels, achieved after intravenous administration, were in•
effective against both types of tachycardia. Such a lack of 
correlation between systemic plasma procainamide level and 
tachycardia suppression was noted consistently, regardless 
of the order of the route of the procainamide administration. 
These observations indicate that the previously proposed 
hysteresis between plasma concentration and procainamide 
effect (20) was not operative in the present study. 
We do not know the detailed electrophysiologic mecha•
nism or mechanisms of the observed superior antiarrhythmic 
response after great cardiac vein procainamide retroinfu•
sion. However, the ability of coronary venous procainamide 
to effectively suppress the tachycardia in a given dog in 
which intravenous procainamide fails to do so, even at rel•
atively higher doses, suggests that the improved antiar•
rhythmic action may have been due to a greater myocardial 
drug concentration. Preferential procainamide distribution 
into and within infarcted and ischemic myocardium with 
attendant higher myocardial procainarnide concentration after 
coronary venous infusion might be responsible for the an•
tiarrhythmic outcome. 
Spontaneous ventricular tachycardia and procain•
amide action. The electrophysiologic mechanisms under•
lying spontaneously occurring ventricular tachycardia 1 day 
after permanent left anterior descending coronary artery oc-
JACC Vol 7, No 3 
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elusion seem to be more complex than originally anticipated, 
Both reentrant and automatic mechanisms (triggered or ab•
normal, or both) have been implicated in the genesis of 
these late phase tachycardias, with ectopic activity arising 
at both epicardial and endocardial sites overlying the in•
farcted left anterior wall (7,21-27), The inability of over•
drive ventricular pacing in the present study to terminate 
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Figure 9. Illustrations from a heart obtained 6 days after per•
manent left anterior descending coronary artery occlusion, Sections 
were made after simultaneous injection of monastral blue dye into 
the left ventricle and monastral red dye into the great cardiac vein 
just before the dog was killed, a, Transverse ventricular slice 
showing distribution of blue dye predominantly in the posterior 
myocardium (supplied by the nonoccluded coronary artery) and 
red dye predominantly in the anterior wall supplied by the occluded 
left anterior descending coronary artery, (b and c are sites of 
histologic sections shown in subsequent panels,) b, Admixture of 
granulation tissue (G) and residual viable myocardium (M) within 
the infarct zone, Note that the red dye is present within vessels in 
both types of tissue (hematoxylin-eosin stain x 40), c, Section 
from normal myocardium at the edge of the infarct showing overlap 
in distribution of the dyes with blue (arrows) as well as red dye 
present within vessels (hematoxylin-eosin stain x 100), 
these tachycardias supports the hypothesis of an automatic 
rather than a reentrant mechanism for most of these tach•
ycardias (7,23-26). However, we cannot exclude the pos•
sibility that some of the beats of the tachycardias are actually 
caused by a reentrant mechanism (24-26). We do not know 
the precise electrophysiologic mechanisms responsible for 
tachycardia conversion to normal sinus rhythm. The ele•
vation of myocardial excitability threshold with prolonga•
tion of refractoriness in ischemic myocardial sites as shown 
by Michelson et al. (28) may well be (at least in part) 
important operative mechanisms. A drug-induced decrease 
in myocardial excitability has been shown to be associated 
with effective arrhythmia suppression I day after coronary 
artery occlusion (14). It is possible that procainamide admin•
istration at certain critical myocardial sites can suppress an 
arrhythmia-generating mechanism (reentry or automaticity, 
or both) by virtue of an appreciable decrease in myocardial 
excitability along with a prolongation of myocardial refrac•
toriness. Further studies are needed to resolve this issue. 
Inducible ventricular tachycardia and actions of pro•
cainamide. It has been suggested that surviving subepi•
cardial and subendocardial cells, along with intramural vi•
able muscle cells within the infarct zone, are involved in 
the genesis and maintenance of inducible ventricular tachy•
cardia by a reentrant mechanism during the chronic phase 
of myocardial ischemia and infarction (29-31), If this is 
the case, then the greater myocardial procainamide concen•
tration achieved in these particular sites through retrograde 
delivery (indicated by both dye distribution and chemical 
assay) may well explain the greater efficacy of coronary 
venous procainamide as compared with systemic intrave•
nous administration. The need for the higher myocardial 
procainamide concentrations for arrhythmia suppression is 
not well understood. Myerburg et al. (32) observed that 
surviving myocardial muscle cells in chronically infarcted 
tissue manifest decreased sensitivity to procainamide, sug•
gesting a need for higher myocardial procainamide concen•
trations to suppress the tachycardia. In their study using a 
cat model with coronary artery occlusion, it was found that 
healed or surviving myocardial fibers in an infarct zone 
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manifest decreased sensitivity to procainamide compared 
with normal myocardial fibers for prolongation of their re•
fractoriness and action potential duration. If such surviving 
cells are engaged in the initiation and maintenance of reen•
trant ventricular tachycardia, then appreciable prolongation 
of their refractory period duration, which presumably occurs 
only with high myocardial procainamide concentration, will 
eventually result in failure to induce tachycardia. Further•
more, a marked decrease in the diastolic excitability of 
surviving abnormal myocardial cells by very high myo•
cardial procainamide concentration (28) could also contrib•
ute to the prevention of inducible reentrant tachycardia. 
The ability of intravenous procainamide to significantly 
decrease the rate of inducible ventricular tachycardia might 
be explained by slowing of the conduction velocity in myo•
cardial fibers engaged in reentrant circuits (18,32,33). Var•
ious degrees of slowing might be expected to occur de•
pending on the sensitivity and responsiveness of these fibers 
to incremental myocardial procainamide concentration, with 
eventual suppression of the tachycardia becoming possible 
only when a sufficient elevation of procainamide concen•
tration develops in critical myocardial sites. Such an effect 
was presumably achieved in two dogs after intravenous pro•
cainamide administration in the present study. Similarly, 
the inability of great cardiac vein procainamide administra•
tion to suppress the arrhythmia in three of nine dogs might 
presumably be explained by the lack of selective concen•
tration of procainamide in myocardial fibers engaged in the 
reentrant circuit. These considerations need further exper•
imental verification. 
Tachycardia termination versus tachycardia induc•
tion with procainamide. The ability to reinduce tachy•
cardia after termination with procainamide of an established 
sustained tachycardia deserves some comments. Procain•
amide manifests use-dependent block of the maximal rate 
of rise of the action potential (Vmax) and conduction in 
partially depolarized cells, an effect further enhanced in the 
presence of elevated extracellular potassium ion concentra•
tion (34,35). During an established rapid tachycardia, pro•
cainamide, by virtue of its use-dependent property, could 
exert a greater depressant effect on conduction on myo•
cardial cells, especially in areas with elevated extracellular 
potassium ion concentrations (35). Because it is likely that 
in partially ischemic zones, with relatively diminished wash•
out capabilities, potassium ions could accumulate during 
the tachycardia in the extracellular spaces, and because it 
is likely that these very sites may be involved in the genesis 
of tachycardia, it is possible that the greater depression of 
conduction velocity at these particular sites could terminate 
the reentrant tachycardia. Later, during normal sinus rhythm 
with a much reduced heart rate, unbinding of procainamide 
from the sodium channel occurs with an attendant decrease 
in the degree of conduction slowing, allowing reentry to 
remerge. This hypothesis remains to be proved. 
Safety of great cardiac vein procainamide retroinfu-
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sion. The administration of procainamide through the great 
cardiac vein in doses of up to 35 mg/kg over a period of 5 
to 10 minutes was hemodynamically well tolerated by the 
conscious supine dog. No severe or sudden deterioration of 
blood pressure or intraventricular conduction abnormalities 
occurred in any of the dogs tested. The safety of coronary 
venous procainamide retroinfusion, however, will require 
further study. In one dog retrograde drug administration was 
associated with the induction of rapid ventricular tachycar•
dia that degenerated to ventricular fibrillation. Because re•
peat attempts at resuscitation failed, the effect of intravenous 
procainamide could not be studied and compared in this 
dog. However, intravenous procainamide was also associ•
ated with induction of ventricular tachycardia in another 
dog, although at slower rate. It could be that in certain 
circumstances procainamide administration is hazardous, and 
that in such cases a highly increased delivery of procain•
amide by retrograde infusion may in itself be deleterious, 
necessitating the use of a much lower initial drug dosage. 
Clinical implications. Retrograde coronary sinus deliv•
ery of hypothermic cardioplegic solutions has been used to 
protect myocardium during aortic valve surgery (36). The 
use of the coronary sinus and the great cardiac vein as an 
alternate and possibly effective route for antiarrhythmic drug 
delivery has not yet been tested in humans. In view of the 
present experimental observations, it seems plausible that 
some patients with "drug refractory" ventricular tachyar•
rhythmias may be considered as suitable candidates in emer•
gency situations in the intensive care setting. However, both 
dosage regimen and safety issues for this new retrograde 
delivery route need to be carefully evaluated. 
We acknowledge Malte Meesmann, MD for his helpful comments and 
Ella Tucker of the Word Processing Center for typing the manuscnpt. 
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